Abstract
During the last years, several drugs has been tried in order to try to diminish the impact of this condition and improve the quality of life of patients who suffer from dystonia. Oral therapy alone or in combination, generates only partial symptom relief and most of the cases end up requiring other more invasive therapies.
References
Jankovic J. Treatment of dystonia. Lancet Neurol. 2006;5(10):864-72. https://doi.org/10.1016/S1474-4422(06)70574-9
Fung VS, Jinnah HA, Bhatia K, Vidailhet M. Assessment of patients with isolated or combined dystonia: an update on dystonia syndromes. Mov Disord. 2013; 28(7):889-98. https://doi.org/10.1002/mds.25549
Albanese A, Lalli S. Is this Dystonia?. Mov Disord. 2009;24(12):1725-73. https://doi.org/10.1002/mds.22597
Snaith A, Wade D. Dystonia. BMJ Clin Evid. 2014;Feb;28.
Jinnah HA, Factor SA. Diagnosis and treatment of dystonia. Neurol Clin. 2015;33(1):77-100. https://doi.org/10.1016/j.ncl.2014.09.002
Svetel M, Kozic D, Stefanoval E, Semnic R, Dragasevic N, Kostic VS. Dystonia in Wilson's disease. Mov Disord. 2001;16(4):719-23.
Delnooz CC, Horstink MW, Tijssen MA, van de Warrenburg BP. Paramedical treatment in primary dystonia: a systematic review. Mov Disord. 2009;24:2187-2198.
Steinberger D, Korinthenberg R, Topka H, et al. Dopa-responsive dystonia: mutation analysis of GCH1 and analysis of therapeutic doses of L-dopa. German Dystonia Study Group. Neurology. 2000;55:1735-1737.
Yaltho TC, Jankovic J, Lotze T. The association of Tourette syndrome and dopa-responsive dystonia. Mov Disord. 2011;26:359-60.
Trender-Gerhard I, Sweeney MG, Schwingenschuh P, et al. Autosomal-dominant GTPCH1-deficient DRD: clinical characteristics and long-term outcome of 34 patients. J Neurol Neurosurg Psychiatry 2009;80:839-45.
Bernal-Pacheco O, Oyama G, Briton A, Andrew B. Singleton, Hubert H. Fernandez, Ramon L. Rodriguez, et al. A novel DYT-5 Mutation with Phenotipic Variability within a Colombian Family. Tremor Other Hyperkinet Mov (N Y). 2013:10:3. https://doi.org/10.7916/D86W98SW
Clot F, Grabli D, Cazeneuve C, Roze E, Castelnau P, Chabrol B, et al. Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with dopa-responsive dystonia. Brain 2009;132:1753-63. https://doi.org/10.1093/brain/awp084
Friedman J, Roze E, Abdenur JE, Chang R, Gasperini S, Saletti V, et al. Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. Ann Neurol. 2012;71(4):520-30. https://doi.org/10.1002/ana.22685.
Bainbridge MN, Wiszniewski W, Murdock DR, Friedman J, Gonzaga-Jauregui C, Newsham I, et al. Whole-genome sequencing for optimized patient management. Sci Transl Med. 2011;3:87re3. https://doi.org/10.1126/scitranslmed.3002243.
Hwang WJ, Calne DB, Tsui JK, de la Fuente-Fernandez R. The long-term response to levodopa in dopa-responsive dystonia. Parkinsonism Relat. Disord. 2001;8(1):1-5.
Calderon DP, Fremont R, Kraenzlin F, Khodakhah K. The neural substrates of rapid-onset dystonia-parkinsonism. Nat Neurosci. 2011;14(3):357-65. https://doi.org/10.1038/nn.2753
Brashear A, Cook JF, Hill DF, et al. Psychiatric disorders in rapid onset dystonia-parkinsonism. Neurology. 2012;79:1168-1173.
Burke RE, Fahn S, Marsden CD. Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology. 1986;36(2):160-64.
Oztekin NS, Saygi SS, Dalkara T, Senses I, Zileli T. High dose anticholinergic therapy (biperiden) in dystonia. Clin Neurol Neurosurg. 1991;93(1):35-7.
Reuss R, Reuter I, Jauss M, Fischer F, Muller SC, Stolz E. Torticollis under cyclobenzaprine. Pharmacology. 2009;84(2):91-2. https://doi.org/10.1159/000227773
Taylor AE1, Lang AE, Saint-Cyr JA, Riley DE, Ranawaya R. Cognitive processes in idiopathic dystonia treated with high-dose anticholinergic therapy: Implications for treatment strategies. Clin Neuropharmacol. 1991;14(1):62-77.
Benarroch EE. GABAB receptors: structure, functions, and clinical implications. Neurology. 2012;78(8):578-84. https://doi.org/10.1212/WNL.0b013e318247cd03
Hou JG, Ondo W, Jankovic J. Intrathecal baclofen for dystonia. Mov Disord. 2001;16(6):1201-02.
Albright AL, Barry MJ, Shafron DH, Ferson SF. Intrathecal baclofen for generalized dystonia. Dev Med Child Neurol. 2001;43(10):652-57.
Cloud LJ, Jinnah HA. Treatment strategies for dystonia. Expert Opin Pharmacother. 2010;11(1):5-15. https://doi.org/10.1517/14656560903426171.
Motta F, Antonello C. Analysis of complications in 430 consecutive pediatric patients treated with intrathecal baclofen therapy: 14-year experience. J Neurosurg Pediatr. 2014;13(3):301-6. https://doi.org/10.3171/2013.11.PEDS13253
Rocque B, Leland A. Intraventricular vs intrathecal baclofen for secondary dystonia: a comparison of complications. Neurosurgery. 2012;70(2 Suppl Operative):321-5.
van Hilten BJ, van de Beek WJ, Hoff JI, et al. Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. N Engl J Med 2000;343:625-630.
Bardutzky J, Tronnier V, Schwab S, Meinck HM. Intrathecal baclofen for stiff-person syndrome: life-threatening intermittent catheter leakage. Neurology. 2003;60(12):1976-78.
Karp BI, Goldstein SR, Chen R, Samii A, Bara-Jimenez W Hallett M. An open trial of clozapine for dystonia. Mov Disord. 1999;14(4):652-57.
Pinninti NR1, Faden J, Adityanjee A. Are Second-Generation Antipsychotics Useful in Tardive Dystonia? Clin Neuropharmacol. 2015;38(5):183-97. https://doi.org/doi:10.1097/WNF.0000000000000106
Grover S1, Hazari N2, Kate N2, et al. Management of tardive syndromes with clozapine: a case series. Asian J Psychiatr. 2014;8:111-4. https://doi.org/doi:10.1016/j.ajp.2013.12.016
Gourzis P1, Skokou M, Soubasi E, Katrivanou A, Polychronopoulos P. Treatment of Tardive Dystonia Induced by Antipsychotics, Old and New. Clin Neuropharmacol. 2015;38(4):121-6. https://doi.org/doi:10.1097/WNF.0000000000000086.
Hanagasi HA1, Bilgic B, Gurvit H, Emre M. Clozapine treatment in oromandibular dystonia. Clin Neuropharmacol. 2004;27(2):84-6.
Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011;(11):1509-23. https://doi.org/doi:10.1586/ern.11.149
Luciano AY, Jinnah HA, Pfeiffer RF, Truong DD, Nance MA, LeDoux MS. Treatment of myoclonus-dystonia syndrome with tetrabenazine. Parkinsonism Relat Disord. 2014;20(12):1423-6. https://doi.org/doi:10.1016/j.parkreldis.2014.09.029
Kaur N, Kumar P, Jamwal S, Deshmukh R, Gauttam V. Tetrabenazina: Spotlight on drug review. Ann Neurosci. 2016;23(3):176-85. https://doi.org/doi:10.1159/000449184
Shapleske J1, Mickay AP, Mckenna PJ. Successful treatment of tardive dystonia with clozapine and clonazepam. Br J Psychiatry. 1996;168(4):516-8.
Davis TL, Charles PD, Burns RS. Clonazepam-sensitive intermittent dystonic tremor. Southern medical journal. 1995; 88(10):1069-71.
Ahmad S, Meeran MK. Treatment of spasmodic torticollis with diazepam. Br Med J. 1979;13(1):127.
Keats S. Dystonia Musculorum Deformans Progressiva. Experience with Diazepam. Dis Nerv Syst. 1963;24:624-9.
Bianchine JR, Bianchine JW. Treatment of spasmodic torticollis with diazepam. South Med J. 1971;64(7):893-4.
Yoshimichi Miyazaki, Wataru Sako, Kotaro Asanuma, Yuishin Izumi, Tetsuro Miki, Ryuji Kaji. Efficacy of zolpidem for dystonia: a study among different subtypes. Front Neurol. 2012;3:58. https://doi.org/doi:10.3389/fneur.2012.00058
Waln O. Jankovic J. Zolpidem improves tardive dyskinesia and akathisia. Mov Disord. 2013; 28(12):1748-9. https://doi.org/doi:10.1002/mds.25480
Evidente VG. Zolpidem improves dystonia in "Lubag" or X-linked dystonia-parkinsonism syndrome. Neurology. 2002;58(4):662-3.
Park IS, Kim JS, An JY, Kim YI, Lee KS. Excellent response to oral zolpidem in a sporadic case of the myoclonus dystonia syndrome. Mov Disord. 2009;24(14):2172-3. https://doi.org/doi:10.1002/mds.22745.
Chen YY, Sy HN, Wu SL. Zolpidem improves akinesia, dystonia and dyskinesia in advanced Parkinson's disease. J Clin Neurosci. 2008;15(8):955-6. https://doi.org/doi:10.1016/j.jocn.2007.07.082
Frucht SJ, Bordelon Y, Houghton WH, Reardam D. A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders. Mov Disord. 2005;20(10):1330-37. https://doi.org/doi:10.1002/mds.20605
Brewer GJ. Novel therapeutic approaches to the treatment of Wilson's disease. Expert Opin Pharmacother. 2006;(783):317-24. https://doi.org/doi:10.1517/14656566.7.3.317
Li X, Jankovic J, Le W. Iron chelation and neuroprotection in neurodegenerative diseases. J Neural Transm 2011;118(3):473-77. https://doi.org/doi:10.1007/s00702-010-0518-0
Dusek P, Jankovic J, Le W. Iron dysregulation in movement disorders. Neurobiol Dis. 2012;46(1):1-18. https://doi.org/doi:10.1016/j.nbd.2011.12.054
Schneider SA, Dusek P, Hardy J, Westenberger A, Jankovic J, Bhatia KP. Genetics and pathophysiology of neurodegeneration with brain iron accumulation (NBIA). Curr Neuropharmacol. 2013;11(1):59-79. https://doi.org/doi:10.2174/157015913804999469
Lucetti C, Nuti A, Gambaccini G, Bernardini S, Brotini S, Manca ML. Mexiletine in the treatment of torticollis and generalized dystonia. Clin Neuropharmacol. 2000;23(4):186-89.
Koshy JC, Sharabi SE, Feldman EM, Hollier LH Jr, Patrinely JR, Soparkar CN. Effect of dietary zinc and phytase supplementation on botulinum toxin treatments. J Drugs Dermatol 2012;11:507- 512.
Zorzi G, Zibordi F, Chiapparini L, Bertini E, Russo L, Piga A. Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial. Mov Disord. 2011;26(9):1756-59.
Velasco-Sanchez D, Aracil A, Montero R, et al. Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia. Cerebellum. 2011(81);10:1-8. https://doi.org/doi:0.1007/s12311-010-0212-7
Sethi KD, Hess DC, Huffnagle VH, Adams RJ. Acetazolamide treatment of paroxysmal dystonia in central demyelinating disease. Neurology; 1992;42(2):919-21.
Termsarasab P, Thammongkolchai T, Frucht ST. Medical Treatment of Dystonia. Journal of Clinical Movement Disorders. 2016;3:19. https://doi.org/doi:10.1186/s40734-016-0047-6
Cao S, Hewett JW, Yokoi F, Lu J, Buckley AC, Burdette AJ, et al. Chemical enhancement of torsin A function in cell and animal models of torsion dystonia. Dis Model Mech. 2010;3(5-6):386-96. https://doi.org/doi:10.1242/dmm.003715
Truong DD, Sandromi P, van der Noort S, Matsumoto RR. Diphenhydramine is effective in the treatment of idiopathic dystonia. Arch Neurol. 1995;52:405-07.
Loscher W, Richter A. Piracetam and levetiracetam, two pyrrolidone derivatives, exert antidystonic activity in a hamster model of paroxysmal dystonia. Eur J Pharmacol. 2000;391(3):251-54.
Hering S, Wenning GK, Seppi K, Poewe W, Mueller J. An open trial of levetiracetam for segmental and generalized dystonia. Mov Disord 2007; 22 (11):1649-51. https://doi.org/doi:10.1002/mds.21597
Pereira AC, Loo WJ, Bamford M, Wroe SJ. Use of lamotrigine to treat paroxysmal kinesigenic choreoathetosis. J Neurol Neurosurg Psychiatry. 2000;68:796-7.
Albanese A, Romito LM, Calandrella D. Therapeutic advances in dystonia. Mov Dis. 2015, 30(11):1547-56. https://doi.org/doi:10.1002/mds.26384
Hainque E, Vidailhet M, Cozic N, Charbonnier-Beaupel F, Thobois S, Tranchant C. A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia. Neurology. 2016 May 3;86(18):1729-35. https://doi.org/doi:10.1212/WNL.0000000000002631.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.